In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it may be effective in preserving the vision of people with wet age-related macular degeneration (AMD). AMD is a leading cause of vision loss in the U.S., affecting an estimated 1.6 million Americans.
The disease is marked by growth of abnormal blood vessels that leak fluid into the central portion of the retina called the macula, which we use for reading, driving and recognizing faces.
The study published on May 16 in The Lancet, reports an exciting new approach in which a virus, similar to the common cold, but altered in the lab so that it is unable to cause disease, is used as a carrier for a gene and is injected into the eye. The virus penetrates retinal cells and deposits a gene, which turns the cells into factories for productions of a therapeutic protein, called sFLT01.
The abnormal blood vessels that cause wet AMD grow because patients have increased production of vascular endothelial growth factor (VEGF) in their retinas. Current treatments require injections of proteins directly into the eye that bind and inactivate VEGF, reducing fluid in the macula and improving vision. However, the therapeutic proteins exit the eye over the course of a month, so patients with wet AMD usually need to return to the clinic for more injections every six to eight weeks in order to stave off vision loss. Eye specialists say the burden and discomfort of the regimen is responsible for many patients not getting injections as frequently as they need, causing vision loss.
Because viruses naturally penetrate cells and leave behind genetic material, the investigators designed their virus to target retinal cells and provide them with a gene that produces sFLT01. Thus, retinal cells become factories that produce the therapeutic protein — potentially eliminating the need to repeatedly inject it.
“This preliminary study is a small but promising step towards a new approach that will not only reduce doctor visits and the anxiety and discomfort associated with repeated injections in the eye, but may improve long-term outcomes because prolonged suppression of VEGF is needed to preserve vision, and that is difficult to achieve with repeated injections because life often gets in the way,” says Peter Campochiaro, M.D., the George S. and Dolores D. Eccles Professor of Ophthalmology at the Johns Hopkins University School of Medicine.
The phase 1 clinical trial involved 19 men and women, 50 years old or older with advanced wet AMD.
Participants were divided into five different groups that received increasing doses from 2X10^8 to 2X10^10 viral particles containing the therapeutic gene in 0.05 mL of fluid. Each group was examined by investigators for signs of adverse reactions for at least 4 weeks before administering a higher dose to the next group.
After the virus deposited the gene, the cells began secreting sFLT01 which bound to VEGF and prevented it from stimulating leakage and growth of abnormal blood vessels. The goal is for the retinal cells infected by the virus to produce enough sFLT01 to permanently stop the progression of AMD.
After monitoring the first three groups and finding no dose-limiting toxicity, the researchers administered the maximum dose to a group of ten participants and observed no serious side effects. “Even at the highest dose, the treatment was quite safe. We found there were almost no adverse reactions in our patients,” Campochiaro says.
For safety and ethical reasons, the study group was composed of people for whom standard approved treatments were highly unlikely to regain vision, meaning in part that only 11 of the 19 had the potential for fluid reduction. Of those eleven patients, four showed dramatic improvements. The amount of fluid in their eyes dropped from severe to almost nothing, just like what is observed with optimal standard treatment, Campochiaro says. In addition, two other participants showed a partial reduction in the amount of fluid in their eyes.
Five participants showed no reduction in fluid levels. Surprisingly, the researchers say, they found that all of the patients who did not show improvement had pre-existing antibodies to the AAV2 virus.
From that result, the researchers conclude that even if further studies affirm the safety and value of their gene therapy, it may have limitations for broad use. That’s because an estimated sixty percent of the U.S. population has been infection with adeno-associated virus, the family of viruses that AAV2 belongs to, and have built an immunity to it. The researchers believe that in these patients, the immune system destroyed the virus before it could insert the therapeutic gene. Campochiaro explains, “The numbers are small and simply show a correlation, so we don’t know if serum antibodies are definitely an impediment, but more work is needed to determine this.”
The Latest on: Wet age-related macular degeneration
Ask the Expert: Macular degeneration can lead to difficulty reading, recognizing faces and performing other fine tasks
on April 17, 2018 at 3:41 am
Age-related macular degeneration is the leading cause of ... Advanced dry macular degeneration has blind areas where there is a dropout of the normal retinal cells. Wet macular degeneration involves abnormal new blood vessels under the retina that leak ... […]
Bucks residents with eye condition, wet age-related macular degeneration, invited to new NHS trial
on April 13, 2018 at 5:21 am
People in Bucks who have and eye condition which causes vision loss have been invited to take part in a new NHS trial in a bid to tackle the condition. The health service is launching a trial to see if one-off radiotherapy can replace eye injections for ... […]
New Retinal Implant Produces Hope of Cure for Macular Degeneration
on April 12, 2018 at 2:00 pm
Non-neovascular age-related macular degeneration (NNAMD) is increasingly common in older adults, Kashani told Healthline. The disease has two forms, wet and dry. They differ in how they progress but end up in the same place — blindness. NNAMD is ... […]
Healthy diet can be key to preventing age-related macular degeneration
on April 10, 2018 at 8:00 pm
There is no permanent cure for age-related macular degeneration (AMD), the leading ... not cured-;with routine eye injections and possibly laser treatment. "With wet macular degeneration, if you catch it early, you can treat it and the visual outcome ... […]
Dear Dr. Roach: Macular degeneration can be treated
on April 9, 2018 at 9:58 am
We are going for a second opinion. Do you have an answer? A: There are two types of age-related macular degeneration, usually called "dry" and "wet." Dry is more common and progresses slowly over years, and it sometimes can progress to wet AMD. […]
Retinal implant designed to replace support cells damaged by dry age-related macular degeneration
on April 6, 2018 at 9:03 am
Age-related macular degeneration (AMD) affects more than 1.75 million individuals ... This publication comes on the heels of a British clinical trial for wet AMD published last week in Nature Biotechnology. "Our goal is to implant healthy RPE to revive ... […]
The vision thing: stem cell procedures produce stunning macular degeneration results
on April 5, 2018 at 7:10 am
Recently, a London-based group reported that two patients suffering from the “wet form” of age-related macular degeneration (AMD), had their eyesight improved by a graft of retinal pigmented epithelial cells (RPE) made from human embryonic stem cells. […]
“Age-Related Macular Degeneration Market”
on March 26, 2018 at 8:35 pm
In the case of dry age-related macular degeneration, the deterioration of the retina occurs. Furthermore, in case of wet macular degeneration, the growth of leaky blood vessels occur under the retina. The function of the macular area (centre of the retina ... […]
via Google News and Bing News